On September 2, Boston Scientific rose 3.12% in regular trading, trading at $49.615 per share, with turnover of $63.56 million. The stock continued its rebound trajectory following a dual blow from a cybersecurity incident and a major product recall that had previously sent shares tumbling over 5%.
On August 25, Boston Scientific identified a cybersecurity incident that disrupted global operations, impairing access to IT systems and business applications, and hindering customer order processing and product shipments across multiple markets. The company disclosed the event in an SEC filing and engaged third-party cybersecurity experts to investigate and contain the threat. Concurrently, the FDA classified the recall of certain lots of its ENROUTE Transcarotid Neuroprotection System as its highest severity level, citing risk of arterial sheath tip separation with potential complications including embolism and stroke. One serious injury was reported.
Market panic has gradually subsided as Boston Scientific confirmed that its China operations remain fully functional and that system restoration efforts are progressing. The stock has now largely recovered to pre-incident levels, supported by broader strength in the Health Care Equipment sector, where Medtronic gained 1.98%, Abbott Laboratories rose 2.15%, and Stryker added 1.37%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments